Genome Pharmaceuticals And Chemicals Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 20-12-2024
- Paid Up Capital ₹ 2.41 M
as on 20-12-2024
- Company Age 30 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 102.39 Cr
as on 20-12-2024
- Satisfied Charges ₹ 100.11 Cr
as on 20-12-2024
- Revenue -23.67%
(FY 2023)
- Profit -22.81%
(FY 2023)
- Ebitda 69.55%
(FY 2023)
- Net Worth 8.59%
(FY 2023)
- Total Assets 7.89%
(FY 2023)
About Genome Pharmaceuticals And Chemicals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.41 M.
The company currently has active open charges totaling ₹102.39 Cr. The company has closed loans amounting to ₹100.11 Cr, as per Ministry of Corporate Affairs (MCA) records.
Mahendra Kumawat and Udit Ruia serve as directors at the Company.
- CIN/LLPIN
U24231MH1994PTC079977
- Company No.
079977
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Aug 1994
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Genome Pharmaceuticals And Chemicals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahendra Kumawat  | Director | 17-Sep-2020 | Current |
| Udit Ruia | Director | 20-Sep-2024 | Current |
Financial Performance of Genome Pharmaceuticals And Chemicals.
Genome Pharmaceuticals And Chemicals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 23.67% decrease. The company also saw a substantial fall in profitability, with a 22.81% decrease in profit. The company's net worth moved up by a moderate rise of 8.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genome Pharmaceuticals And Chemicals?
Unlock access to Genome Pharmaceuticals And Chemicals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sbicap Trustee Company Limited Creation Date: 24 Jul 2024 | ₹65.69 Cr | Open |
Others Creation Date: 23 Mar 2011 | ₹36.70 Cr | Open |
Others Creation Date: 06 Apr 2022 | ₹3.08 Cr | Satisfied |
How Many Employees Work at Genome Pharmaceuticals And Chemicals?
Unlock and access historical data on people associated with Genome Pharmaceuticals And Chemicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genome Pharmaceuticals And Chemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genome Pharmaceuticals And Chemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
